Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?

Shares of Tempus AI (TEM) gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare by integrating cutting-edge genetic testing with AI-driven insights, especially testing capabilities for inherited cancer risk. Per the acquisition deal, Tempus AI's total consideration for Ambry includes $375 million in cash and $225 million in equity. The deal is anticipated to be closed in the first quarter o ...